市场调查报告书

免疫疗法药的全球市场:成长率,趋势及预测分析(2019年~2024年)

Immunotherapy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 649742
出版日期 内容资讯 英文 116 Pages
商品交期: 2-3个工作天内
价格
免疫疗法药的全球市场:成长率,趋势及预测分析(2019年~2024年) Immunotherapy Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日内容资讯: 英文 116 Pages
简介

全球免疫疗法药市场在2019年~2024年的预测期间内,预计将以13%的年复合成长率成长。推动免疫疗法药市场成长的主要原因,为标靶治疗比传统治疗方法的采用增多,生物相似药的出现,慢性疾病和文明病的盛行率上升,单株抗体的需求高涨等。

本报告提供全球免疫疗法药市场相关调查分析,市场概要,市场动态,市场区隔,各地区的市场分析,竞争情形,主要企业等相关的系统性资讯。

目录

第1章 简介

  • 调查的成果
  • 调查的前提条件
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 市场成长要素
    • 标靶治疗比传统的疗法的采用增多
    • 生物相似药的出现
    • 慢性疾病和文明病的盛行率上升
    • 单株抗体的需求高涨
  • 市场阻碍因素
    • 免疫疗法治疗的高成本
    • 在产品开发周期的高损耗率
  • 波特的五力分析
    • 新加入厂商的威胁
    • 买主/消费者谈判力
    • 供应商谈判力
    • 替代产品的威胁
    • 竞争力的强度

第5章 市场区隔

  • 药物的各类型
    • 单株抗体
    • 疫苗
    • 免疫查核点抑制剂
    • α干扰素及β
    • 白细胞介素
    • 其他
  • 各治疗领域
    • 癌症
    • 自体免疫疾病及发炎性疾病
    • 感染疾病
    • 其他
  • 各终端用户
    • 医院/诊疗所
    • 癌症研究中心
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲地区
    • 南美

第6章 竞争情形

  • 企业概要
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • UbiVac

第7章 市场机会及未来趋势

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 60463

The immunotherapy drugs market is anticipated to record a CAGR of 13% during the forecast period. The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies. Furthermore, immunotherapy is widely used in cancer treatment

For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.

Key Market Trends

Cancer is Expected to Hold the Major Share in the Therapy Area Segment

  • Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow.
  • There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators.​
  • These therapies are used for many types of cancer and their advanced stages. The side-effects of cancer immunotherapy vary, depending upon the immunotherapy being used. Some of the popular immunotherapy drugs are Rituxan, Yervoy, Adcetris, and Zevalin, among several others.​
  • The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.

According to the estimates of the American Cancer Society, in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.​

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy market in the United States. In March 2019, Roche's Tecentriq in combination with Abraxane received U.S.FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.

Competitive Landscape

The immunotherapy drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches R&D, expansions to gain competitive advantage. In August 2019, U.S.FDA approved pexidartinib (TURALIO™, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
    • 4.2.2 Emergence of Biosimilars
    • 4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
    • 4.2.4 Rising Demand for Monoclonal Antibodies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Immunotherapy Treatment
    • 4.3.2 High Attrition Rate in the Product Development Cycle
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Drug
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Vaccines
      • 5.1.2.1 Preventive Vaccines
      • 5.1.2.2 Therapeutic Vaccines
    • 5.1.3 Checkpoint Inhibitors
    • 5.1.4 Interferons Alpha and Beta
    • 5.1.5 Interleukins
    • 5.1.6 Other Types of Drugs
  • 5.2 By Therapy Area
    • 5.2.1 Cancer
    • 5.2.2 Autoimmune and Inflammatory Diseases
    • 5.2.3 Infectious Diseases
    • 5.2.4 Other Therapy Areas
  • 5.3 By End User
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Cancer Research Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca plc
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 GlaxoSmithKline plc
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 UbiVac

7 MARKET OPPORTUNITIES AND FUTURE TRENDS